molecule of gut-GLI as an immunoreactant. Production of the region-specific anti-glucagon sera is achieved only by chance, in so far as the whole molecule of glucagon is used as the immunogen. Peptide hormone fragments have been used as efficient substrates in the production of region-specific antisera. Use of the N-terminal segment of porcine glucagon, which lacks the Cterminal region, may be useful in producing antisera specific to the N-terminal or central region of the glucagon. In addition, the use of the segment as an immunogen excludes the possible heterogeneity of antisera due to concomitant elicitation of antibodies against the C-terminal portion of glucagon when the whole molecule is used. We have previously reported that all antisera produced against haptenic antigen, glucagon 19-29, were specific for pancreatic glucagon (Imagawa et al., 1979; Yanaihara et al., 1979) . The present paper provides the characterization of the antisera produced using des-Asn28, Thr29, Homoser27-glucagon (CNBr-glucagon) as haptenic immunogen, which was prepared by the treatment of porcine glucagon with cyanogen bromide. Development of a radioimmunoassay for total GLI using the antisera is also described.
Materials and Methods
Glucagon related peptides and immunogen CNBr-glucagon was prepared by a modification of the method of Lin et al. (1975) . Porcine glucagon (80mg) was dissolved in 70% formic acid and a 60-fold molar excess (over glucagon) of cyanogen bromide (Wako Pure Chem. Co.) was added. The mixture was stirred for 24hrs at room temperature and lyophilized. The products were gelfiltered on a BioGel P-2 column. The peak fraction eluting at void volume was pooled and lyophilized.
Approximately 45mg of white powder was obtained. Amino acid analysis of this material showed the absence of methionine, and amino acid composition of the acid hydrolysate of CNBr-glucagon was Lys (1) 0.85, His (1) 0.75, Arg (2) 2.02, Asp (3) 3.25, Thr (2) 2.15, Ser (4) 4.23, Glu (3) 2.87, Gly (1) 1.05, Ala (1) 1.00, Val (1) 0.95, Leu (2) 2.15, Tyr (2) 2.13, Phe (2) 2.06. High pressure liquid chromatography revealed no detectable peak of pancreatic glucagon in this haptenic preparation.
Glucagon fragments 1-12, 13-17 and 19-29 were prepared by trypsin digestion of glucagon in the manner described previously (Imagawa et al., 1979) . Highly purified synthetic porcine VIP (Yanaihara. et al., 1977, a) and porcine secretin (Yanaihara et al., mark) were employed in the present study.
Coupling of the CNBr-glucagon to BSA was carried out in the following manner. The CNBr-glucagon (40mg) and BSA (60mg) were dissolved in 20 ml of 0.1M borate-HCl, pH 9.0, and 0.2M glutaraldehyde (5ml) was added dropwise with constant stirring while pH of the reaction mixture was ad- Production of antisera CNBr-glucagon-BSA conjugate was emulsified in Freund's complete adjuvant and injected in to seven male New Zealand white rabbits via a subcutaneous route at multiple sites at 2week intervals for 2 months. Each rabbit received 2mg of the conjugate (0.8mg of CNBr-glucagon). All antisera thus obtained were examined for their ability to bind with (peak-I, see below) in canine jejunal extract.
For comparison with the antisera produced in this study, antisera raised against glucagon 19-29 fragment as described previously (Yanaihara et al., 1979) , especially one of these antisera, Denmaik) which is the Nterminal specific, were used as references. Preparation of extracts of canine stomach, ileum and pancreas, and gelfiltration procedure Gut-GLI was extracted from mucosal scraps of the canine small intestine (ileum) according to the modification of Kenny's procedure (1955 Collection of plasma Nine healthy volunteers and six gastrectomized subjects were orally given 50g glucose (OGTT). The gastrectomized group had undergone antorectomy, two with a gastrojejunostomy (Billroth II) and four with a gastroduodenostomy (Billroth I) reconstraction. Blood samples were drawn from the antecubital vein at 0, 15, 30, 60, 90 and 120min after glucose load, and collected into ice chilled tubes containing 500 tivities in the ileum extract (upper panel in Fig. 2) was monitered with the OAL-196 one before insulin and the other between insulin and glucagon markers. The ratio of the values in peak-I estimated with OAL-196 to that with OAL-123 was about 27. In the elution pattern of the immunoreactivity in the stomach extract (middle panel in Fig. 2 ), five peaks were observed. The largest peak corresponding to the glucagon marker was similar in size to that measured with OAL-123. In the case of the pancreatic extract (lower panel), a single peak eluted in a region similar to that of the glucagon marker was observed with both assay systems. (1:20,000), (e) (1:176,000), (f) (1:352,000), (g) (1:66,000) (h) (1:200,000), and (i) 000 glucagon to nearly the same extent as with pancreatic glucagon and porcine glicentin, whereas the C-terminal specific antiserum OAL-123 showed low crossreactivity with gut-GLI, which was only 2% that of pancreatic glucagon. Antiserum OAL-196 did not react with the C-terminal fragment, glucagon (19-29), synthetic porcine VIP or secretin at all. On the other hand, antiserum OAL-196 crossreacted with the Nterminal fragments, glucagon (1-12) and (13-17), but very weakly.
Development of a radioimmunoassay for plasma total GLI using antiserum 10). Serial dilution curves of human plasma were parallel to the standard curve. Intra-assay variability was determined in the assay with OAL-196 using 20 replicates of three different human plasma samples with different GLI levels. The intra-assay coefficients of variation ranged from 3.4 to 5.0% (Table 2a) . For the estimation of inter-assay variability, three different plasma samples were examined on six occasions with OAL-196. The interassay coefficient of variation ranged from 6.0 to 7.3% (Table 2b) The intra-assay variability of three different human plasma samples was determined in the antiserum OAL-196 system.
In the determination of the inter-assay variability, the same plasma samples were examined on six separation occasions. Recovery studies were performed by adding crystalline glucagon to two different samples, containing 490.5 and 668.9pg/ml of endogenous glucagon.
Six different amounts of glucagon were added to each sample. . In the group of normal subjects, plasma GLI increased significantly at 30min, whereas the plasma, immunoreactive glucagon (IRG) level measured with OAL-123 was lowered. In the gastrectomized subject, plasma GLI measured with OAL-196 elicited a marked increase following an oral glucose load. 
